doi: 10.1093/jtm/taaa041.
Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19
Affiliations
- PMID: 32186711
- PMCID: PMC7184445
- DOI: 10.1093/jtm/taaa041
Item in Clipboard
Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19
J Travel Med.
.
Abstract
Intravenous infusions of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in experimental animals increase the numbers of angiotensin-converting enzyme 2 (ACE2) receptors in the cardiopulmonary circulation. ACE2 receptors serve as binding sites for SARS-CoV-2 virions in the lungs. Patients who take ACEIs and ARBS may be at increased risk of severe disease outcomes due to SARS-CoV-2 infections.
Comment in
-
Keep taking your ACE inhibitors and ARBs during the COVID 19 pandemic.J Travel Med. 2020 May 18;27(3):taaa045. doi: 10.1093/jtm/taaa045. J Travel Med. 2020. PMID: 32268374 Free PMC article. No abstract available.
Similar articles
-
A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19.Am J Cardiol. 2020 Sep 1;130:159-161. doi: 10.1016/j.amjcard.2020.05.038. Epub 2020 Jun 2. Am J Cardiol. 2020. PMID: 32624189 Free PMC article. No abstract available.
-
COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?JAMA. 2020 May 12;323(18):1769-1770. doi: 10.1001/jama.2020.4812. JAMA. 2020. PMID: 32208485 No abstract available.
-
COVID-19: The heart of the issue.J Card Surg. 2020 Aug;35(8):2112. doi: 10.1111/jocs.14684. Epub 2020 Jun 16. J Card Surg. 2020. PMID: 32542802 Free PMC article. No abstract available.
-
Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19.Hypertens Res. 2020 Jul;43(7):648-654. doi: 10.1038/s41440-020-0455-8. Epub 2020 Apr 27. Hypertens Res. 2020. PMID: 32341442 Free PMC article. Review.
-
COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?J Endocrinol Invest. 2020 Aug;43(8):1053-1060. doi: 10.1007/s40618-020-01318-1. Epub 2020 Jun 3. J Endocrinol Invest. 2020. PMID: 32495299 Free PMC article. Review.
Cited by
-
Discontinuation of Antihypertensive Medications on the Outcome of Hospitalized Patients With Severe Acute Respiratory Syndrome-Coronavirus 2.Hypertension. 2021 Jul;78(1):165-173. doi: 10.1161/HYPERTENSIONAHA.121.17328. Epub 2021 Jun 9. Hypertension. 2021. PMID: 34106731 Free PMC article.
-
Antiviral potential of diminazene aceturate against SARS-CoV-2 proteases using computational and in vitro approaches.Chem Biol Interact. 2022 Nov 1;367:110161. doi: 10.1016/j.cbi.2022.110161. Epub 2022 Sep 15. Chem Biol Interact. 2022. PMID: 36116513 Free PMC article.
-
Potentially modifiable factors to reduce severity of COVID-19 in type 2 diabetes.Nutr Diabetes. 2020 Aug 12;10(1):30. doi: 10.1038/s41387-020-00133-0. Nutr Diabetes. 2020. PMID: 32788586 Free PMC article. No abstract available.
-
COVID-19: breaking down a global health crisis.Ann Clin Microbiol Antimicrob. 2021 May 18;20(1):35. doi: 10.1186/s12941-021-00438-7. Ann Clin Microbiol Antimicrob. 2021. PMID: 34006330 Free PMC article. Review.
-
Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19.Arch Med Res. 2020 Jul;51(5):464-467. doi: 10.1016/j.arcmed.2020.04.006. Epub 2020 Apr 15. Arch Med Res. 2020. PMID: 32327293 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
